Daihan Pharmaceutical Co.Ltd Cash Flow Quality Index
Daihan Pharmaceutical Co.Ltd cash flow quality index. Daihan Pharmaceutical Co.Ltd (023910) has a Cash Flow Quality Index of 1.09x as of September 2025. Operating cash flow of ₩9.47 Billion exceeds net income of ₩8.72 Billion, indicating high earnings quality where cash backs reported profits. Explore Daihan Pharmaceutical Co.Ltd cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Daihan Pharmaceutical Co.Ltd (2014–2024)
Cash flow quality index of Daihan Pharmaceutical Co.Ltd from 2014 to 2024. Historical Cash Flow Quality Index for Daihan Pharmaceutical Co.Ltd across 11 annual periods. Values consistently above 1.0x indicate high-quality earnings. See Daihan Pharmaceutical Co.Ltd net asset quality index to measure how much of total assets are equity-financed.
Daihan Pharmaceutical Co.Ltd Cash Flow Quality Index by Year (2014–2024)
Daihan Pharmaceutical Co.Ltd cash flow quality index by year from 2014 to 2024. Year-by-year earnings quality comparison for Daihan Pharmaceutical Co.Ltd. For the full cash flow conversion analysis, see 023910 cash flow conversion.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.06x | ₩35.64 Billion | ₩33.76 Billion | ▼ -22.8% |
| 2023 | 1.37x | ₩38.86 Billion | ₩28.43 Billion | ▲ +17.7% |
| 2022 | 1.16x | ₩29.00 Billion | ₩24.96 Billion | ▼ -35.2% |
| 2021 | 1.79x | ₩40.62 Billion | ₩22.67 Billion | ▼ -7.4% |
| 2020 | 1.93x | ₩33.63 Billion | ₩17.38 Billion | ▲ +54.5% |
| 2019 | 1.25x | ₩35.26 Billion | ₩28.17 Billion | ▼ -20.6% |
| 2018 | 1.58x | ₩44.94 Billion | ₩28.52 Billion | ▲ +91.3% |
| 2017 | 0.82x | ₩20.45 Billion | ₩24.83 Billion | ▼ -47.9% |
| 2016 | 1.58x | ₩27.92 Billion | ₩17.66 Billion | ▲ +21.2% |
| 2015 | 1.30x | ₩17.98 Billion | ₩13.78 Billion | ▲ +43.4% |
| 2014 | 0.91x | ₩9.48 Billion | ₩10.42 Billion | — |